title: CD4+ T-cells lymphocytosis and reduction of neutrophils during treatment with adalimumab: Challenge and dechallenge study.
authors.forename: Francesco
authors.initials: F
authors.lastname: Ursini
authors.forename: Saverio
authors.initials: S
authors.lastname: Naty
authors.forename: Caterina
authors.initials: C
authors.lastname: Bruno
authors.forename: Marilena
authors.initials: M
authors.lastname: Calabria
authors.forename: Francesco
authors.initials: F
authors.lastname: Spagnolo
authors.forename: Rosa Daniela
authors.initials: RD
authors.lastname: Grembiale
mesh_terms: D000068879:Adalimumab; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000150:complications / Q000188:drug therapy*; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000150:complications; D008218:Lymphocytosis / Q000209:etiology*; D008875:Middle Aged; D009504:Neutrophils / Q000187:drug effects*; D015663:Osteoporosis, Postmenopausal / Q000150:complications
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D000068879:Adalimumab